Genmab Announces US Food and Drug Administration Accepts for Priority Review Biologics License Application (BLA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)

Genmab A/S announced that the FDA has accepted for Priority Review the Biologics License Application for subcutaneous epcoritamab, an investigational bispecific antibody, for the treatment of patients with relapsed/refractory large B cell lymphoma after two or more lines of systemic therapy.
[Genmab A/S]
Full Article

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News